<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957242</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00017156</org_study_id>
    <secondary_id>5U10HL080413-05</secondary_id>
    <secondary_id>671</secondary_id>
    <nct_id>NCT00957242</nct_id>
  </id_info>
  <brief_title>AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>ACE-IPF</acronym>
  <official_title>AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the effectiveness of warfarin in patients with IPF. Approximately 256
      patients will be randomized 1:1 to either warfarin or placebo. Patients will return at week 1
      for a safety review and every 16 weeks for 48 weeks. The primary endpoint in the study is the
      time to either death, non-bleeding/non-elective hospitalization, or a drop of greater than
      10% in forced vital capacity (FVC) from baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      ACE-IPF was a double-blind, randomized, placebo-controlled trial of an oral warfarin dose
      adjusted to an international normalized ratio (INR) response of 2.0 to 3.0, compared with a
      sham dose-adjusted placebo. The trial was originally designed as an event-driven study with a
      treatment period of up to 144 weeks. Given the slow rate of recruitment and higher than
      anticipated event rates seen in another Idiopathic Pulmonary Fibrosis Clinical Research
      Network (IPFnet) trial, the protocol was modified to have a maximum treatment period of 48
      weeks after eleven patients were enrolled in the study. Participants were to be seen at
      screening, baseline, and at 16, 32, and 48 weeks after enrollment.

      Outcome measures:

      The primary outcome was a composite endpoint based on the time to all-cause mortality;
      non-elective, non-bleeding hospitalization; or a decrease in the absolute FVC ≥10% from
      baseline value. Secondary outcome measures included rates of mortality, hospitalization,
      respiratory-related hospitalization, acute exacerbation, bleeding, cardiovascular events, and
      changes over time in FVC, six-minute walk test distance, diffusing capacity of lung for
      carbon monoxide (DLCO), plasma fibrin D-dimer levels, and quality of life (QOL) assessments.

      Data Analysis Continuous variables at baseline were expressed as means (standard deviations)
      and medians (25th and 75th percentiles). Categorical variables at baseline were expressed as
      counts and percentages. Unadjusted estimates of event rates for time-to-event variables were
      computed using the Kaplan-Meier estimator with comparisons based on the log-rank test
      statistic. The primary hypothesis was tested using a Cox proportional hazards regression
      model, comparing the treatment effect on the primary composite endpoint. Pre-specified
      covariates in this model included an indicator variable for the treatment group and the DLCO
      measurement from the baseline assessment.

      Randomization:

      Subjects were randomly assigned to study arms in a 1:1 ratio, using a permuted-block design
      with varying block sizes, to receive either warfarin or matched placebo. Subjects were
      stratified by clinical center and a DLCO threshold of 35% of predicted. Randomization lists
      were generated by the study data coordinating center (DCC) and provided to a phone- and
      web-enabled registration system (Almac Clinical Services, Inc.) that allowed sites to enroll
      subjects and receive study kits while keeping the study team and subjects blinded to
      treatment assignment.

      INR testing and monitoring:

      Study subjects were provided two strengths of warfarin tablets (1 mg and 2.5 mg) or matching
      placebos. Subjects measured their INR with encrypted meters (INRatio®, Alere, San Diego, CA)
      at least weekly. Home monitoring was validated by plasma INR measurement at the week 1 and 16
      visits. Individual INR meters and test strips were replaced and subjects were reinstructed if
      meter INR readings varied by more than 30% from the laboratory INR. Efficacy of home INR
      measures were determined by time-in-target INR range of all patients, calculated on the basis
      of linear interpolation, 12 after excluding readings taken at baseline, during initial
      warfarin titration (until INR ≥ 2.0), study drug interruption, or following the
      discontinuation of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Excess of mortality in the treatment group created safety concerns.
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death, Non-bleeding/Non-elective Hospitalization, or &gt;10% Drop in Forced Vital Capacity</measure>
    <time_frame>Events up to 48 weeks</time_frame>
    <description>Death, non-bleeding/non-elective hospitalization, or &gt;10% drop in forced vital capacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>maximum of 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC) From Baseline to 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>Week-16 change from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Hospitalizations</measure>
    <time_frame>maximum 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>maximum of 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF)</measure>
    <time_frame>maximum of 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory-related Hospitalizations</measure>
    <time_frame>maximum 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality or Morbidity</measure>
    <time_frame>maximum of 48 weeks</time_frame>
    <description>Measured at 48 Weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute Walk Distance (6MWD)</measure>
    <time_frame>Change from baseline to last visit (maximum of 48 weeks)</time_frame>
    <description>The 6MWD is a measure of exercise tolerance. Change in exercise tolerance is calculated at the latest time point (up to 48 weeks) minus the earliest time point (at baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Score St. George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Week 16 Change from Baseline</time_frame>
    <description>The SGRQ is a quality of life measurement used to assess respiratory well being with a 0*-100 range (*indicates better health--lower is better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) From Baseline to 16 Weeks</measure>
    <time_frame>Week 48 / Final Visit</time_frame>
    <description>The DLCO measures the partial pressure difference between inspired and expired carbon monoxide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin D-dimer Change From Baseline to 16 Weeks</measure>
    <time_frame>maximum of 48 weeks</time_frame>
    <description>Biomarker that measures biologic activities in patients as opposed to response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral warfarin titrated to an international normalization ratio (INR) of 2-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo (1mg or 2.5mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
    <arm_group_label>warfarin</arm_group_label>
    <other_name>warfarin sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Oral placebo (1mg or 2.5mg)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of IPF

          -  Age between 35 and 80, inclusive

          -  Capable of understanding and signing consent

          -  Progression despite conventional therapy (standard of care). Progression defined as:

               1. Worsened dyspnea

               2. FVC decreased by &gt;=10% predicted OR

               3. DLCO decreased by &gt;=10% absolute OR

               4. Reduction of oxygenation saturation &gt;= 5% with or without exertion on a constant
                  oxygen (02) administration

               5. Worsened radiographic findings (chest x-ray or high-resolution computed
                  tomography)

        Exclusion Criteria:

          -  Current enrollment in another investigational protocol

          -  Current treatment with an investigational drug (i.e., participating in an active
             investigational drug protocol) within the previous 4 weeks or 5 times the half-life of
             the investigational agent, whichever is longer, prior to screening

          -  Subject is actively listed for lung transplantation at the time of enrollment

          -  Subjects who will not be able to perform/complete the study, in the judgment of the
             physician investigator or coordinator, for at least 3 months. For example:

               1. Subject has current signs or symptoms of severe, progressive or uncontrolled
                  comorbid illnesses such as: renal, hepatic, hematologic, gastrointestinal,
                  endocrine, cardiac, neurologic, or cerebral disease, or any laboratory
                  abnormality which would pose/suggest a risk to the subject during participation
                  in the study.

               2. Subject has a transplanted organ requiring immunosuppression

               3. History of substance abuse (drugs or alcohol) within the 2 years prior to
                  screening, history of noncompliance to medical regimens, inability or
                  unwillingness to perform INR monitoring, or other condition/circumstance that
                  could interfere with the subject's adherence to protocol requirements (e.g.
                  psychiatric disease, lack of motivation, travel, etc).

               4. Have any known active malignancy or have a history of malignancy within the
                  previous 2 years (an example of an exception is a non-melanoma skin cancer that
                  has been treated with no evidence of recurrence for at least 3 months) that might
                  increase the risk of bleeding.

          -  Estimated life expectancy &lt; 12 months due to a non-pulmonary cause.

          -  Subject has another respiratory disease that is predominant (as judged by the PI) in
             addition to IPF.

          -  Anticoagulation-related exclusions include:

               1. Current anticoagulation therapy with warfarin

               2. Increased risk of bleeding (e.g. uncorrectable inherited or acquired bleeding
                  disorder)

               3. Platelet count &lt; 100,000 or hematocrit &lt; 30% or &gt; 55%

               4. History of severe gastrointestinal bleeding within 6 months of screening

               5. History of cerebral vascular accident (CVA) within 6 months of screening

               6. High risks of falls as judged by the PI

               7. Surgery or major trauma within the past 30 days

               8. Pregnancy, or lack of use of birth control method in women of childbearing age

               9. Any condition that, in the determination of the PI, is likely to require
                  anticoagulation therapy during the study.

              10. Clopidogrel and aspirin combination therapy for &gt; 30 days duration is
                  exclusionary.

                  (Aspirin monotherapy [81-325 mg daily] or clopidogrel monotherapy are acceptable.
                  Combination clopidogrel and aspirin &lt;=81mg/day for ≤30 days is also acceptable.
                  NSAIDS are discouraged; acetaminophen may be substituted.)

              11. Patients on prasugrel are excluded. Prasugrel must be stopped for one week prior
                  to starting study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Galen Toews, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gail Weinmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rob Kaner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College at Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Talmadge King, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joe Lasky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Loyd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Imre Noth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ganesh Raghu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesse Roman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay Ryu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Lynch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Anstrom, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joao deAndrade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Chapman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lake Morrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kallay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Highland Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Sahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marilyn Glassberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milton Rossman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Fitzgerald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Beth Scholand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Ettinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danielle Antin-Ozerkis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Hospital - University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Research Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <results_first_submitted>March 4, 2013</results_first_submitted>
  <results_first_submitted_qc>August 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2013</results_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IPF</keyword>
  <keyword>Warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were randomized at 25 U.S. sites in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 weeks. International normalized ratios (INR) were monitored using encrypted home point-of-care devices that allowed blinding of study therapy.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Oral placebo (1mg or 2.5mg)
placebo : Oral placebo (1mg or 2.5mg)</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>Oral warfarin titrated to an INR of 2-3
warfarin : Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Oral placebo (1mg or 2.5mg)
placebo : Oral placebo (1mg or 2.5mg)</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>Oral warfarin titrated to an INR of 2-3
warfarin : Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="7.4"/>
                    <measurement group_id="B2" value="67.3" spread="7.1"/>
                    <measurement group_id="B3" value="67" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Death, Non-bleeding/Non-elective Hospitalization, or &gt;10% Drop in Forced Vital Capacity</title>
        <description>Death, non-bleeding/non-elective hospitalization, or &gt;10% drop in forced vital capacity.</description>
        <time_frame>Events up to 48 weeks</time_frame>
        <population>All participants per intention-to-treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>matched placebo</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>warfarin sodium titrated to an INR of 2.0-3.0</description>
          </group>
        </group_list>
        <measure>
          <title>Death, Non-bleeding/Non-elective Hospitalization, or &gt;10% Drop in Forced Vital Capacity</title>
          <description>Death, non-bleeding/non-elective hospitalization, or &gt;10% drop in forced vital capacity.</description>
          <population>All participants per intention-to-treat (ITT)</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was designed to have 90% power to detect a difference in 48-week event free rates of 70% for the warfarin group versus 50% for the placebo group. A total of at least 95 adjudicated primary endpoints were required to achieve 90% power with 2-sided, type I error rate of 0.05 and a 1:1 randomization ratio. These calculations yielded a requisite total sample size of 256.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Regression, Cox</method>
            <method_desc>Prespecified covariates in the model included an indicator variable for the treatment group and the DLCO measurement from the baseline assessment.</method_desc>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>2.47</ci_upper_limit>
            <estimate_desc>Warfarin vs. Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>maximum of 48 weeks</time_frame>
        <population>All participants per intention-to-treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <population>All participants per intention-to-treat (ITT)</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Cox Proportional</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>5.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.44</ci_lower_limit>
            <ci_upper_limit>17.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Vital Capacity (FVC) From Baseline to 16 Weeks</title>
        <description>Week-16 change from Baseline</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Vital Capacity (FVC) From Baseline to 16 Weeks</title>
          <description>Week-16 change from Baseline</description>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.21"/>
                    <measurement group_id="O2" value="-0.01" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>t-value</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Hospitalizations</title>
        <time_frame>maximum 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Hospitalizations</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>Cox Proportional</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>4.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Events</title>
        <time_frame>maximum of 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Events</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Cox Proportional</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>9.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF)</title>
        <time_frame>maximum of 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF)</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Cox Proportional</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>12.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory-related Hospitalizations</title>
        <time_frame>maximum 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory-related Hospitalizations</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Cox Proportional</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>16.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Mortality or Morbidity</title>
        <description>Measured at 48 Weeks</description>
        <time_frame>maximum of 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Mortality or Morbidity</title>
          <description>Measured at 48 Weeks</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>Cox Proportional</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>3.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6-minute Walk Distance (6MWD)</title>
        <description>The 6MWD is a measure of exercise tolerance. Change in exercise tolerance is calculated at the latest time point (up to 48 weeks) minus the earliest time point (at baseline).</description>
        <time_frame>Change from baseline to last visit (maximum of 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6-minute Walk Distance (6MWD)</title>
          <description>The 6MWD is a measure of exercise tolerance. Change in exercise tolerance is calculated at the latest time point (up to 48 weeks) minus the earliest time point (at baseline).</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.41" spread="41.31"/>
                    <measurement group_id="O2" value="8.68" spread="178.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7222</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>t-value</param_type>
            <param_value>10.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.57</ci_lower_limit>
            <ci_upper_limit>71.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Score St. George's Respiratory Questionnaire (SGRQ)</title>
        <description>The SGRQ is a quality of life measurement used to assess respiratory well being with a 0*-100 range (*indicates better health--lower is better).</description>
        <time_frame>Week 16 Change from Baseline</time_frame>
        <population>All participants per intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Score St. George's Respiratory Questionnaire (SGRQ)</title>
          <description>The SGRQ is a quality of life measurement used to assess respiratory well being with a 0*-100 range (*indicates better health--lower is better).</description>
          <population>All participants per intention-to-treat</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="11.28"/>
                    <measurement group_id="O2" value="3.24" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>t-value</param_type>
            <param_value>-1.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.04</ci_lower_limit>
            <ci_upper_limit>3048</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) From Baseline to 16 Weeks</title>
        <description>The DLCO measures the partial pressure difference between inspired and expired carbon monoxide.</description>
        <time_frame>Week 48 / Final Visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) From Baseline to 16 Weeks</title>
          <description>The DLCO measures the partial pressure difference between inspired and expired carbon monoxide.</description>
          <units>mL/min/mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="2.55"/>
                    <measurement group_id="O2" value="-1.34" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.957</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>t-value</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.67</ci_lower_limit>
            <ci_upper_limit>1076</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibrin D-dimer Change From Baseline to 16 Weeks</title>
        <description>Biomarker that measures biologic activities in patients as opposed to response.</description>
        <time_frame>maximum of 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral placebo (1mg or 2.5mg)</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrin D-dimer Change From Baseline to 16 Weeks</title>
          <description>Biomarker that measures biologic activities in patients as opposed to response.</description>
          <units>mg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread="0.20"/>
                    <measurement group_id="O2" value="-.61" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>t-value</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collected during study participation period plus 4 weeks from last dose of study agent. Maximum of 52 weeks. Mean collection period with study termination was 32 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Oral placebo (1mg or 2.5mg)
placebo : Oral placebo (1mg or 2.5mg)</description>
        </group>
        <group group_id="E2">
          <title>Warfarin</title>
          <description>Oral warfarin titrated to an INR of 2-3
warfarin : Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cario-Respiratory Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>GI Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Haeamothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Imre Noth, MD, Associate Professor of Medicine</name_or_title>
      <organization>University of Chicago Hospital</organization>
      <phone>773-834-1832</phone>
      <email>inoth@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

